Publicacions en què col·labora amb Didier P. Blaise (31)

2023

  1. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

    Transplantation and Cellular Therapy, Vol. 29, Núm. 3, pp. 184.e1-184.e9

  2. Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission

    British Journal of Haematology, Vol. 201, Núm. 6, pp. 1169-1178

  3. Prediction of Nonrelapse Mortality in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation with Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis

    HemaSphere

2022

  1. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 11, pp. 1657-1663

  2. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10

  3. Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9)

    Bone Marrow Transplantation

  4. Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age

    American Journal of Hematology, Vol. 97, Núm. 8, pp. 1065-1074

  5. Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 9, pp. 587.e1-587.e7

  6. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 4, pp. 562-571

2021

  1. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 5, pp. 1047-1055

  2. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 9, pp. 2194-2202

  3. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1842-1849

  4. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia

    Leukemia, Vol. 34, Núm. 10, pp. 2766-2775

  2. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 5, pp. 936-942

  3. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia

    American Journal of Hematology, Vol. 95, Núm. 10, pp. 1200-1208

  4. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

  5. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: A comparative study of the ALWP EBMT

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

2019

  1. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

    Cancer, Vol. 125, Núm. 1, pp. 90-98

  2. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 3, pp. 522-528